Phibro Animal Health Q4 Revenue Up 39%

Phibro Animal Health (PAHC) reported robust Q4 FY2025 results, with GAAP revenue surging 39% to $378.7 million and adjusted EBITDA rising 49%, largely driven by the successful integration of the Zoetis medicated feed additive acquisition and strong international demand. While these figures surpassed expectations, GAAP gross margin declined by 2.9 percentage points to 29.0% due to acquisition-related costs and higher distribution expenses. Management issued strong FY2026 guidance, projecting 12% sales growth and 25% adjusted EBITDA growth, indicating confidence in continued expansion despite margin pressures.

Analysis

Phibro Animal Health (PAHC) reported a transformative fourth quarter for fiscal year 2025, primarily driven by the successful integration of its largest-ever acquisition of Zoetis's medicated feed additive (MFA) portfolio. GAAP revenue surged 39% year-over-year to $378.7 million, with the acquired Zoetis products contributing $94.5 million in sales and fueling a 53% increase in the core Animal Health segment. Profitability metrics also showed significant strength, with adjusted EBITDA growing 49%, outpacing revenue growth and signaling effective operating leverage from the acquisition. However, this top-line success was tempered by a notable contraction in GAAP gross margin, which declined by 2.9 percentage points to 29.0% due to acquisition-related costs, a less favorable product mix, and higher distribution expenses. Despite this margin pressure, management issued robust guidance for fiscal year 2026, projecting approximately 12% sales growth and a 25% increase in adjusted EBITDA, reflecting strong confidence in sustained global demand and the long-term earnings power of its expanded portfolio. The company's financial position appears stable, with gross leverage at 3.1x and a consistent quarterly dividend of $0.12 per share.

Key Decisions for Investors

• Investors should view the strong FY2026 guidance, particularly the projected 25% growth in adjusted EBITDA, as a key indicator of management's confidence in successfully integrating the Zoetis acquisition and capitalizing on its expanded market position.
• It is critical to monitor gross margin performance in subsequent quarters, as the reported 2.9 percentage point decline highlights a significant risk that persistent cost pressures could offset the benefits of strong revenue growth.
• Given the gross leverage of 3.1x post-acquisition, investors should track free cash flow generation and the company's ability to de-lever to ensure the balance sheet can support future growth initiatives and the stable dividend policy.